The GeneConvene Virtual Institute is an initiative of the GeneConvene Global Collaborative, a program within the Foundation for the National Institutes of Health that advances best practices for genetic biocontrol technologies such as those using gene drive.
Gene drive and other genetic biocontrol technologies are emerging technologies with implications for public health, conservation and agriculture. Conversations and discussions about these technologies will benefit from well-informed stakeholders and other interested parties.
New WHO Guidance
The 2014 WHO Guidance Framework for Testing Genetically Modified Mosquitoes published by the WHO Special Programme for Research and Training in Tropical Diseases (WHO-TDR) and the Foundation for the National Institutes of Health (FNIH) has been revised and updated.
This revised version takes into account the technical progress made and lessons learned in this rapidly advancing field of research. Best practices recommended in the 2021 WHO Guidance framework for Testing Genetically Modified Mosquitoes will further contribute to the comparability of results and credibility of conclusions in order to facilitate decision-making by countries interested in the potential use of GMMs as public health tools for the control of vector-borne diseases.
GeneConvene Virtual Institute eNewsletter
The Latest About Gene Drive and Genetic Biocontrol
The GeneConvene Virtual Institute is built on a database of content in the categories shown in the tab labels below. Content coming into the Virtual Institute in these categories can be seen in each tab as well as all of the content in each of the categories, organized chronologically.
Featured Content
Efficacy of Wolbachia-Infected Mosquito Deployments for the Control of Dengue
A. Utarini, C. Indriani, R. A. Ahmad, W. Tantowijoyo, E. Arguni, M. R. Ansari, E. Supriyati, D. S. Wardana, Y. Meitika, I. Ernesia, I. Nurhayati, E. Prabowo, B. Andari, B. R. Green, L. Hodgson, Z. Cutcher, E. Rancès, P. A. Ryan, S. L. O’Neill, S. M. Dufau, New England Journal of Medicine, 384:2177-2186. 2021.
Wolbachia-infected cell
Image credit: Scott O’Neill CC BY2.5
BACKGROUND Aedes aegypti mosquitoes infected with the wMel strain of Wolbachia pipientis are less susceptible than wild-type A. aegypti to dengue virus infection. METHODS We conducted a cluster-randomized trial involving releases of wMel-infected A. aegypti mosquitoes for the control of dengue in Yogyakarta, Indonesia. We randomly assigned 12 geographic clusters to receive deployments of wMel-infected A. aegypti (intervention clusters) and 12 clusters to receive no deployments (control clusters). All clusters practiced local mosquito-control measures as usual. A test-negative design was used to assess the efficacy of the intervention. Patients with acute undifferentiated fever who presented to local primary care clinics and were 3 to 45 years of age were recruited. Laboratory testing was used to identify participants who had virologically confirmed dengue (VCD) and those who were test-negative controls. The primary end point was symptomatic VCD of any severity caused by any dengue virus serotype. RESULTS After successful introgression of wMel into the intervention clusters, 8144 participants were enrolled; 3721 lived in intervention clusters, and 4423 lived in control clusters. In the intention-to-treat analysis, VCD occurred in 67 of 2905 participants (2.3%) in the intervention clusters and in 318 of 3401 (9.4%) in the control clusters (aggregate odds ratio for VCD, 0.23; 95% confidence interval [CI], 0.15 to 0.35; P=0.004). The protective efficacy of the intervention was 77.1% (95% CI, 65.3 to 84.9) and was similar against the four dengue virus serotypes. The incidence of hospitalization for VCD was lower among participants who lived in intervention clusters (13 of 2905 participants [0.4%]) than among those who lived in control clusters (102 of 3401 [3.0%]) (protective efficacy, 86.2%; 95% CI, 66.2 to 94.3).
More related to this:
Population genetics of Anopheles funestus, the African malaria vector, Kenya
